Drug Patent Expirations for May 22 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
body { font-family:Calibri, tahoma, arial,
sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial,
sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1,
.zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px;
border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0
3px;}.xtop, .xbottom { display:block; background:transparent;
font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden;
}.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff;
border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0
5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 {
margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent {
display:block; border:0 solid #444; border-width:0 1px; height:auto; }*
html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt;
background-color:#FFF; }

<td align=right–>
ADVERTISE
HERE
FDA Orange Book archives from 2005 to
present<!–/td>

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 22 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
ACTONEL Warner
Chilcott
risedronate sodium 6,096,342*PED May
22, 2012
VIRAMUNE Boehringer
Ingelheim
nevirapine 5,366,972*PED May
22, 2012
VIRAMUNE
XR
Boehringer Ingelheim nevirapine 5,366,972*PED May
22, 2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Like this:


Comments are closed.

%d bloggers like this: